Wroński M, Arbit E, Russo P, Galicich J H
Neurosurgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Urology. 1996 Feb;47(2):187-93. doi: 10.1016/S0090-4295(99)80413-0.
Metastases are frequently diagnosed among patients with renal cell carcinoma (RCC). Of 709 patients with brain metastases (BMET) who were operated on at our institution between 1974 and 1993, 50 (7%) were of renal origin.
Medical records were reviewed retrospectively. Survival time was calculated by the Kaplan-Meier method and Cox proportional hazards model.
There were 38 men and 12 women. The median age was 60 years. The primary RCC was resected in 47 patients. Forty patients had a metachronous diagnosis of RCC and BMET. Median interval between the diagnosis of RCC and BMET was 17 months. In all 50 patients overall median survival (MS) from diagnosis of primary RCC was 31.4 months and from craniotomy was 12.6 months. Postoperative mortality was 10% (5 patients). In patients with primary RCC in the left kidney (n=25) versus right kidney (n=25) median survival from craniotomy was longer; 21.3 versus 7.4 months (P<0.014). Twenty-three patients (46%) had intratumoral hemorrhage. Eight patients had cerebellar metastasis (MS, 3.0 months) and 9 had multiple metastases resected (MS, 7.6 months). Thirty-eight patients had both brain and pulmonary metastases, and 16 of them had pulmonary resection (MS, 18.6 versus 8.0 months; P<0.03). Twenty-two patients received whole-brain radiation therapy (WBRT) after craniotomy and 18 did not receive WBRT (MS, 13.3 versus 14.5 months; P<0.62). The 1-year, 2-year, 3-year, and 5-year survival was 51%, 24%, 22%, and 8.5% respectively.
Only the resection of lung metastasis, supratentorial location of BMET, left-sided localization of primary RCC, and lack of neurologic deficit before craniotomy were statistically significant prognostic factors in Cox regression analysis. In the absence of effective systemic treatment, we suggest that patients with BMET from RCC be considered for operative resection for treatment and palliation.
肾细胞癌(RCC)患者中经常诊断出转移情况。1974年至1993年间在我们机构接受手术的709例脑转移(BMET)患者中,50例(7%)起源于肾脏。
对病历进行回顾性分析。生存时间采用Kaplan-Meier法和Cox比例风险模型计算。
男性38例,女性12例。中位年龄为60岁。47例患者的原发性RCC被切除。40例患者在RCC和BMET诊断上存在异时性。RCC诊断与BMET诊断之间的中位间隔为17个月。所有50例患者从原发性RCC诊断开始的总体中位生存期(MS)为31.4个月,从开颅手术开始为12.6个月。术后死亡率为10%(5例患者)。左肾原发性RCC患者(n = 25)与右肾原发性RCC患者(n = 25)相比,开颅手术后的中位生存期更长;分别为21.3个月和7.4个月(P < 0.014)。23例患者(46%)发生瘤内出血。8例患者有小脑转移(MS,3.0个月),9例患者切除了多发转移灶(MS,7.6个月)。38例患者同时有脑和肺转移,其中16例进行了肺切除术(MS,18.6个月对8.0个月;P < 0.03)。22例患者在开颅手术后接受了全脑放疗(WBRT),18例未接受WBRT(MS,13.3个月对14.5个月;P < 0.62)。1年、2年、3年和5年生存率分别为51%、24%、22%和8.5%。
在Cox回归分析中,只有肺转移灶切除、BMET位于幕上、原发性RCC位于左侧以及开颅手术前无神经功能缺损是具有统计学意义的预后因素。在缺乏有效的全身治疗的情况下,我们建议对RCC脑转移患者考虑进行手术切除以进行治疗和缓解症状。